cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25345/c5nk36j3h
title: MassIVE MSV000098945 - Quantitative Peptidomics Reveals an FRK1-Derived Peptide Induced by Flg22 That Activates Local and AtCAPE9-Dependent Systemic Immunity
title: Quantification of 1-amino-cyclopropane-1-carboxylic acid (ACC), salicylic acid (SA), jasmonic acid (JA), jasmonoyl-isoleucine (JA-Ile), and abscisic acid (ABA) levels in leaves of plants treated with 1 uM FIKA1 over a time course.
DOI: 10.14272/lszlynamghrfjj-uhfffaoysa-n/chmo0000595
title: 13C nuclear magnetic resonance spectroscopy (13C NMR) ()
title: InChI=1S/C16H22O2/c1-11-6-8-12(9-7-11)13-10-16(13,5)14(17)18-15(2,3)4/h6-9,13H,10H2,1-5H3

description: dataset for 13C nuclear magnetic resonance spectroscopy (13C NMR)
DOI: 10.14272/lszlynamghrfjj-uhfffaoysa-n/chmo0000630
title: infrared absorption spectroscopy (IR) ()
title: InChI=1S/C16H22O2/c1-11-6-8-12(9-7-11)13-10-16(13,5)14(17)18-15(2,3)4/h6-9,13H,10H2,1-5H3

description: dataset for infrared absorption spectroscopy (IR)
DOI: 10.14272/lszlynamghrfjj-uhfffaoysa-n/chmo0000593
title: 1H nuclear magnetic resonance spectroscopy (1H NMR) ()
title: InChI=1S/C16H22O2/c1-11-6-8-12(9-7-11)13-10-16(13,5)14(17)18-15(2,3)4/h6-9,13H,10H2,1-5H3

description: dataset for 1H nuclear magnetic resonance spectroscopy (1H NMR)
DOI: 10.14272/lszlynamghrfjj-uhfffaoysa-n.1
title: tert-butyl 1-methyl-2-(p-tolyl)cyclopropane-1-carboxylate
title: InChI=1S/C16H22O2/c1-11-6-8-12(9-7-11)13-10-16(13,5)14(17)18-15(2,3)4/h6-9,13H,10H2,1-5H3

description: This is a physical chemical entity[CHEBI_24431] associated with a molecule[CHEBI_25367].
 The molecule[CHEBI_25367] can be described by the following structural desciptors[cheminf_000085]:
 InChI descriptor[cheminf_000113]: InChI=1S/C16H22O2/c1-11-6-8-12(9-7-11)13-10-16(13,5)14(17)18-15(2,3)4/h6-9,13H,10H2,1-5H3, and canonical SMILES descriptor[cheminf_000007]: Cc1ccc(cc1)C1CC1(C)C(=O)OC(C)(C)C, and by the IUPAC name[cheminf_000107]: .
 
 The physical chemical entity[CHEBI_24431] has a component solvent[CHEBI_46787] which is described by the canonical SMILES descriptor[cheminf_000007]:
 
 The physical chemical entity[CHEBI_24431] has the following Sample ID as registered in the research data repository chemotion (www.chemotion-repository.net, https://doi.org/10.25504/FAIRsharing.iagXcR): CRS-7787

 The physical chemical entity[CHEBI_24431] can be described by the physical descriptors [CHEMINF_000025]:
 Melting point descriptor[CHEMINF_000256]: 
 Boiling point descriptor[CHEMINF_000257]: 
 Refractive index descriptor[CHEMINF_000253]:

 The physical chemical entity[CHEBI_24431] can be further described by the following assays[OBI:0000070][CHMO:0001133]:
 
 CHMO:0000595 | 13C nuclear magnetic resonance spectroscopy (13C NMR)
 
 CHMO:0000630 | infrared absorption spectroscopy (IR)
 
 CHMO:0002337 | electrospray ionisation quadrupole detection (ESI Q Trap)
 
 CHMO:0002136 | chiral stationary phase high-performance liquid chromatography (CSP HPLC)
 
 CHMO:0000593 | 1H nuclear magnetic resonance spectroscopy (1H NMR)
 
 The physical chemical entity[CHEBI_24431] was deposited to the Molecule Archive of the Karlsruhe Insitute of Technology (KIT) with the following Sample ID: 

 Used ontologies:
 CHEBI - Chemical Entities of Biological Interest
 CHEMINF - chemical information ontology (information entities about chemical entities)
 CHMO - Chemical Methods Ontology
 OBI - Ontology for Biomedical Investigations
DOI: 10.14272/lszlynamghrfjj-uhfffaoysa-n/chmo0002136
title: chiral stationary phase high-performance liquid chromatography (CSP HPLC) ()
title: InChI=1S/C16H22O2/c1-11-6-8-12(9-7-11)13-10-16(13,5)14(17)18-15(2,3)4/h6-9,13H,10H2,1-5H3

description: dataset for chiral stationary phase high-performance liquid chromatography (CSP HPLC)
DOI: 10.14272/lszlynamghrfjj-uhfffaoysa-n/chmo0002337
title: electrospray ionisation quadrupole detection (ESI Q Trap) ()
title: InChI=1S/C16H22O2/c1-11-6-8-12(9-7-11)13-10-16(13,5)14(17)18-15(2,3)4/h6-9,13H,10H2,1-5H3

description: dataset for electrospray ionisation quadrupole detection (ESI Q Trap)
DOI: 10.14272/imobskyatudxme-uhfffaoysa-n.1
title: C16H22O2
title: InChI=1S/C16H22O2/c1-11-7-6-8-12(9-11)13-10-16(13,5)14(17)18-15(2,3)4/h6-9,13H,10H2,1-5H3

description: This is a physical chemical entity[CHEBI_24431] associated with a molecule[CHEBI_25367].
 The molecule[CHEBI_25367] can be described by the following structural desciptors[cheminf_000085]:
 InChI descriptor[cheminf_000113]: InChI=1S/C16H22O2/c1-11-7-6-8-12(9-11)13-10-16(13,5)14(17)18-15(2,3)4/h6-9,13H,10H2,1-5H3, and canonical SMILES descriptor[cheminf_000007]: Cc1cccc(c1)C1CC1(C)C(=O)OC(C)(C)C, and by the IUPAC name[cheminf_000107]: .
 
 The physical chemical entity[CHEBI_24431] has a component solvent[CHEBI_46787] which is described by the canonical SMILES descriptor[cheminf_000007]:
 
 The physical chemical entity[CHEBI_24431] has the following Sample ID as registered in the research data repository chemotion (www.chemotion-repository.net, https://doi.org/10.25504/FAIRsharing.iagXcR): CRS-7781

 The physical chemical entity[CHEBI_24431] can be described by the physical descriptors [CHEMINF_000025]:
 Melting point descriptor[CHEMINF_000256]: 
 Boiling point descriptor[CHEMINF_000257]: 
 Refractive index descriptor[CHEMINF_000253]:

 The physical chemical entity[CHEBI_24431] can be further described by the following assays[OBI:0000070][CHMO:0001133]:
 
 CHMO:0000630 | infrared absorption spectroscopy (IR)
 
 CHMO:0002136 | chiral stationary phase high-performance liquid chromatography (CSP HPLC)
 
 CHMO:0000593 | 1H nuclear magnetic resonance spectroscopy (1H NMR)
 
 CHMO:0000595 | 13C nuclear magnetic resonance spectroscopy (13C NMR)
 
 CHMO:0002337 | electrospray ionisation quadrupole detection (ESI Q Trap)
 
 The physical chemical entity[CHEBI_24431] was deposited to the Molecule Archive of the Karlsruhe Insitute of Technology (KIT) with the following Sample ID: 

 Used ontologies:
 CHEBI - Chemical Entities of Biological Interest
 CHEMINF - chemical information ontology (information entities about chemical entities)
 CHMO - Chemical Methods Ontology
 OBI - Ontology for Biomedical Investigations
DOI: 10.14272/imobskyatudxme-uhfffaoysa-n/chmo0000593
title: 1H nuclear magnetic resonance spectroscopy (1H NMR) ()
title: InChI=1S/C16H22O2/c1-11-7-6-8-12(9-11)13-10-16(13,5)14(17)18-15(2,3)4/h6-9,13H,10H2,1-5H3

description: dataset for 1H nuclear magnetic resonance spectroscopy (1H NMR)
DOI: 10.14272/imobskyatudxme-uhfffaoysa-n/chmo0000595
title: 13C nuclear magnetic resonance spectroscopy (13C NMR) ()
title: InChI=1S/C16H22O2/c1-11-7-6-8-12(9-11)13-10-16(13,5)14(17)18-15(2,3)4/h6-9,13H,10H2,1-5H3

description: dataset for 13C nuclear magnetic resonance spectroscopy (13C NMR)
DOI: 10.14272/imobskyatudxme-uhfffaoysa-n/chmo0000630
title: infrared absorption spectroscopy (IR) ()
title: InChI=1S/C16H22O2/c1-11-7-6-8-12(9-11)13-10-16(13,5)14(17)18-15(2,3)4/h6-9,13H,10H2,1-5H3

description: dataset for infrared absorption spectroscopy (IR)
DOI: 10.14272/imobskyatudxme-uhfffaoysa-n/chmo0002136
title: chiral stationary phase high-performance liquid chromatography (CSP HPLC) ()
title: InChI=1S/C16H22O2/c1-11-7-6-8-12(9-11)13-10-16(13,5)14(17)18-15(2,3)4/h6-9,13H,10H2,1-5H3

description: dataset for chiral stationary phase high-performance liquid chromatography (CSP HPLC)
DOI: 10.14272/imobskyatudxme-uhfffaoysa-n/chmo0002337
title: electrospray ionisation quadrupole detection (ESI Q Trap) ()
title: InChI=1S/C16H22O2/c1-11-7-6-8-12(9-11)13-10-16(13,5)14(17)18-15(2,3)4/h6-9,13H,10H2,1-5H3

description: dataset for electrospray ionisation quadrupole detection (ESI Q Trap)
DOI: 10.15468/dl.3p5qtw
title: Occurrence Download

description: A dataset containing 21190 species occurrences available in GBIF matching the query:
{
 "and" : [
 {
 "or" : [
 "PublishingCountry is Colombia",
 {
 "and" : [
 "Country is Colombia",
 {
 "not" : {
 "Issue" : [
 "is Country coordinate mismatch"
 ]
 }
 }
 ]
 }
 ]
 },
 "GadmGid is one of (COL.30.11_2)"
 ]
}

 The dataset includes 21190 records from 59 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0029698-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.17632/bcrh56xrkv
title: Investigation of the Effect of Cardiorespiratory Fitness on Cardiometabolic Risk Factors and Testosterone Levels in Firefighters

description: This dataset originates from a cross-sectional study investigating the relationship between cardiorespiratory fitness, cardiometabolic risk factors, and testosterone levels in professional firefighters. Data were collected in 2024 from male firefighters employed by a municipal fire department in Türkiye. The dataset includes demographic information (age), anthropometric measurements (weight, height, BMI, waist circumference), biochemical markers (fasting glucose, lipid profile, total testosterone), and physical fitness indicators (estimated VO₂max, MET scores). The data are structured in Microsoft Excel format and were prepared for statistical analysis using SPSS.
DOI: 10.17632/bcrh56xrkv.1
title: Investigation of the Effect of Cardiorespiratory Fitness on Cardiometabolic Risk Factors and Testosterone Levels in Firefighters

description: This dataset originates from a cross-sectional study investigating the relationship between cardiorespiratory fitness, cardiometabolic risk factors, and testosterone levels in professional firefighters. Data were collected in 2024 from male firefighters employed by a municipal fire department in Türkiye. The dataset includes demographic information (age), anthropometric measurements (weight, height, BMI, waist circumference), biochemical markers (fasting glucose, lipid profile, total testosterone), and physical fitness indicators (estimated VO₂max, MET scores). The data are structured in Microsoft Excel format and were prepared for statistical analysis using SPSS.
DOI: 10.17632/rdfc9hb88h.1
title: Development of a Mucosal Immune-Enhancing Oral Vaccine Against Porcine Epidemic Diarrhea Virus Using Lactobacillus paracasei

description: We attempted to enhance the specific immune ability of the mucosa, Lactobacillus paracasei served as the host strain to express the fusion of the protective antigen S1 of PEDV, the M cell-targeting peptide Co1, the dendritic cell-targeting peptides (6aa), and the mucosal immune adjuvant LTB, thereby obtaining a candidate strain pPG-Co1-6aa-S1-LTB/27-2. Pregnant mice that received oral immunization with recombinant microorganisms demonstrated a notable increase in serum IgG antibodies that are specific to anti-PEDV, in addition to intestinal mucus and fecal SIgA antibodies, both of which exhibited in vitro neutralizing activity. Additionally, pregnant mice had considerably higher serum levels of IFN-γ, IL-2, IL-4, and IL-10. Notably, the level of anti-PEDV specific SIgA antibodies of the newborn mice delivered by the pregnant mice was also significantly elevated. The aforementioned findings show that the recombinant bacteria pPG-Co1-6aa-S1-LTB/27-2 can produce maternal antibodies and strongly stimulate humoral, cellular, and mucosal immune responses in pregnant mice.
Figure 1. Illustrative diagram showing the creation of recombinant plasmids.
Figure 2. Immunization protocol and sampling schedule.
Figure 3. Identification and protein expression analysis of recombinant L.paracasei 27-2. A. PCR identification of recombinant plasmids. M: Trans 2k plus DNA marker. B. Western blot analysis was used to confirm the fusion protein's expression. M: Pre-stained protein marker. C. Analysis of binding activity of recombinant lactobacillus expressing LTB protein.
Figure 4. Proteins from different species were presented on the surface of Lactobacillus paracasei.
Figure 5. Biological characterization analysis. A. Growth curve determination. B. The protein stability of the recombinant strains was assessed through Western blot analysis.
Figure 6. Anti-PEDV-specific IgG antibody levels in the serum, anti-PEDV-specific SIgA antibody levels in the intestinal mucus and fecal are listed in A, B, and C, respectively.
Figure 7. Measurement of neutralizing activity in intestinal serum IgG and mucus SIgA antibody levels in vaccinated pregnant mice.
Figure 8. Measure the blood cytokine levels in pregnant mice that have received recombinant strains and PBS vaccinations. The mean ± SEM of three separate experiments is used to illustrate the results.
Figure 9. Quantities of anti-PEDV specific SIgA antibodies in the intestinal mucus of neonatal mice.
DOI: 10.17632/rdfc9hb88h.2
title: Development of a Mucosal Immune-Enhancing Oral Vaccine Against Porcine Epidemic Diarrhea Virus Using Lactobacillus paracasei

description: We attempted to enhance the specific immune ability of the mucosa, Lactobacillus paracasei served as the host strain to express the fusion of the protective antigen S1 of PEDV, the M cell-targeting peptide Co1, the dendritic cell-targeting peptides (6aa), and the mucosal immune adjuvant LTB, thereby obtaining a candidate strain pPG-Co1-6aa-S1-LTB/27-2. Pregnant mice that received oral immunization with recombinant microorganisms demonstrated a notable increase in serum IgG antibodies that are specific to anti-PEDV, in addition to intestinal mucus and fecal SIgA antibodies, both of which exhibited in vitro neutralizing activity. Additionally, pregnant mice had considerably higher serum levels of IFN-γ, IL-2, IL-4, and IL-10. Notably, the level of anti-PEDV specific SIgA antibodies of the newborn mice delivered by the pregnant mice was also significantly elevated. The aforementioned findings show that the recombinant bacteria pPG-Co1-6aa-S1-LTB/27-2 can produce maternal antibodies and strongly stimulate humoral, cellular, and mucosal immune responses in pregnant mice.
Figure 1. Illustrative diagram showing the creation of recombinant plasmids.
Figure 2. Immunization protocol and sampling schedule.
Figure 3. Identification and protein expression analysis of recombinant L.paracasei 27-2. A. PCR identification of recombinant plasmids. M: Trans 2k plus DNA marker. B. Western blot analysis was used to confirm the fusion protein's expression. M: Pre-stained protein marker. C. Analysis of binding activity of recombinant lactobacillus expressing LTB protein.
Figure 4. Proteins from different species were presented on the surface of Lactobacillus paracasei.
Figure 5. Biological characterization analysis. A. Growth curve determination. B. The protein stability of the recombinant strains was assessed through Western blot analysis.
Figure 6. Anti-PEDV-specific IgG antibody levels in the serum, anti-PEDV-specific SIgA antibody levels in the intestinal mucus and fecal are listed in A, B, and C, respectively.
Figure 7. Measurement of neutralizing activity in intestinal serum IgG and mucus SIgA antibody levels in vaccinated pregnant mice.
Figure 8. Measure the blood cytokine levels in pregnant mice that have received recombinant strains and PBS vaccinations. The mean ± SEM of three separate experiments is used to illustrate the results.
Figure 9. Quantities of anti-PEDV specific SIgA antibodies in the intestinal mucus of neonatal mice.
DOI: 10.17632/rdfc9hb88h.3
title: Development of a Mucosal Immune-Enhancing Oral Vaccine Against Porcine Epidemic Diarrhea Virus Using Lactobacillus paracasei

description: We attempted to enhance the specific immune ability of the mucosa, Lactobacillus paracasei served as the host strain to express the fusion of the protective antigen S1 of PEDV, the M cell-targeting peptide Co1, the dendritic cell-targeting peptides (6aa), and the mucosal immune adjuvant LTB, thereby obtaining a candidate strain pPG-Co1-6aa-S1-LTB/27-2. Pregnant mice that received oral immunization with recombinant microorganisms demonstrated a notable increase in serum IgG antibodies that are specific to anti-PEDV, in addition to intestinal mucus and fecal SIgA antibodies, both of which exhibited in vitro neutralizing activity. Additionally, pregnant mice had considerably higher serum levels of IFN-γ, IL-2, IL-4, and IL-10. Notably, the level of anti-PEDV specific SIgA antibodies of the newborn mice delivered by the pregnant mice was also significantly elevated. The aforementioned findings show that the recombinant bacteria pPG-Co1-6aa-S1-LTB/27-2 can produce maternal antibodies and strongly stimulate humoral, cellular, and mucosal immune responses in pregnant mice.
Figure 1. Illustrative diagram showing the creation of recombinant plasmids.
Figure 2. Immunization protocol and sampling schedule.
Figure 3. Identification and protein expression analysis of recombinant L.paracasei 27-2. A. PCR identification of recombinant plasmids. M: Trans 2k plus DNA marker. B. Western blot analysis was used to confirm the fusion protein's expression. M: Pre-stained protein marker. C. Analysis of binding activity of recombinant lactobacillus expressing LTB protein.
Figure 4. Proteins from different species were presented on the surface of Lactobacillus paracasei.
Figure 5. Biological characterization analysis. A. Growth curve determination. B. The protein stability of the recombinant strains was assessed through Western blot analysis.
Figure 6. Anti-PEDV-specific IgG antibody levels in the serum, anti-PEDV-specific SIgA antibody levels in the intestinal mucus and fecal are listed in A, B, and C, respectively.
Figure 7. Measurement of neutralizing activity in intestinal serum IgG and mucus SIgA antibody levels in vaccinated pregnant mice.
Figure 8. Measure the blood cytokine levels in pregnant mice that have received recombinant strains and PBS vaccinations. The mean ± SEM of three separate experiments is used to illustrate the results.
Figure 9. Quantities of anti-PEDV specific SIgA antibodies in the intestinal mucus of neonatal mice.
DOI: 10.17632/rdfc9hb88h.4
title: Development of a Mucosal Immune-Enhancing Oral Vaccine Against Porcine Epidemic Diarrhea Virus Using Lactobacillus paracasei

description: We attempted to enhance the specific immune ability of the mucosa, Lactobacillus paracasei served as the host strain to express the fusion of the protective antigen S1 of PEDV, the M cell-targeting peptide Co1, the dendritic cell-targeting peptides (6aa), and the mucosal immune adjuvant LTB, thereby obtaining a candidate strain pPG-Co1-6aa-S1-LTB/27-2. Pregnant mice that received oral immunization with recombinant microorganisms demonstrated a notable increase in serum IgG antibodies that are specific to anti-PEDV, in addition to intestinal mucus and fecal SIgA antibodies, both of which exhibited in vitro neutralizing activity. Additionally, pregnant mice had considerably higher serum levels of IFN-γ, IL-2, IL-4, and IL-10. Notably, the level of anti-PEDV specific SIgA antibodies of the newborn mice delivered by the pregnant mice was also significantly elevated. The aforementioned findings show that the recombinant bacteria pPG-Co1-6aa-S1-LTB/27-2 can produce maternal antibodies and strongly stimulate humoral, cellular, and mucosal immune responses in pregnant mice.
Figure 1. Illustrative diagram showing the creation of recombinant plasmids.
Figure 2. Immunization protocol and sampling schedule.
Figure 3. Identification and protein expression analysis of recombinant L.paracasei 27-2. A. PCR identification of recombinant plasmids. M: Trans 2k plus DNA marker. B. Western blot analysis was used to confirm the fusion protein's expression. M: Pre-stained protein marker. C. Analysis of binding activity of recombinant lactobacillus expressing LTB protein.
Figure 4. Proteins from different species were presented on the surface of Lactobacillus paracasei.
Figure 5. Biological characterization analysis. A. Growth curve determination. B. The protein stability of the recombinant strains was assessed through Western blot analysis.
Figure 6. Anti-PEDV-specific IgG antibody levels in the serum, anti-PEDV-specific SIgA antibody levels in the intestinal mucus and fecal are listed in A, B, and C, respectively.
Figure 7. Measurement of neutralizing activity in intestinal serum IgG and mucus SIgA antibody levels in vaccinated pregnant mice.
Figure 8. Measure the blood cytokine levels in pregnant mice that have received recombinant strains and PBS vaccinations. The mean ± SEM of three separate experiments is used to illustrate the results.
Figure 9. Quantities of anti-PEDV specific SIgA antibodies in the intestinal mucus of neonatal mice.
DOI: 10.15468/dl.rfdsjx
title: Occurrence Download

description: A dataset containing 1633 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Dolichotis patagonum (Zimmermann, 1780)"
 ]
}

 The dataset includes 1633 records from 83 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0011899-250415084134356/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.15133178
title: Evaluating E3SM Global Storm-Resolving Model Simulations of Deep Convection: Insights from DP-SCREAM during TRACER

description: This dataset contains model output from the Doubly-Periodic Simplified Cloud-Resolving E3SM Atmosphere Model (DP-SCREAM) used to evaluate model performance during the TRACER campaign along with the script. For reference, simulations from the E3SMv2 Single Column Model (SCM) are included to enable direct comparison with DP-SCREAM at a 3km horizontal resolution over a three-month period. To investigate model sensitivity, additional DP-SCREAM 3km simulations were conducted within the SHOC (Simplified Higher Order Closure) scheme for August 2022. These include experiments with increased mixing length (mix_incr_run) and enhanced buoyancy flux (bf_run) which were compared to the control run (DP-SCREAM 3km run for August 2022). Horizontal resolution sensitivity was evaluated by comparing DP-SCREAM simulations at 3km and 0.5km from August 5 to August 15, 2022. To analyze the formation of unrealistic fog, we used the month-long DP-SCREAM 3 km simulation for August 2022, supplemented by a series of time-initialized runs starting on August 6 at 00:00, 06:00, 12:00, and 18:00 local time. The dataset also contains the precipitation cluster statistics for the runs.
DOI: 10.5281/zenodo.15133179
title: Evaluating E3SM Global Storm-Resolving Model Simulations of Deep Convection: Insights from DP-SCREAM during TRACER

description: This dataset contains model output from the Doubly-Periodic Simplified Cloud-Resolving E3SM Atmosphere Model (DP-SCREAM) used to evaluate model performance during the TRACER campaign. For reference, simulations from the E3SMv2 Single Column Model (SCM) are included to enable direct comparison with DP-SCREAM at a 3km horizontal resolution over a three-month period. To investigate model sensitivity, additional DP-SCREAM 3km simulations were conducted within the SHOC (Simplified Higher Order Closure) scheme for August 2022. These include experiments with increased mixing length (mix_incr_run) and enhanced buoyancy flux (bf_run) which were compared to the control run (DP-SCREAM 3km run for August 2022). Horizontal resolution sensitivity was evaluated by comparing DP-SCREAM simulations at 3km and 0.5km from August 5 to August 15, 2022. To analyze the formation of unrealistic fog, we used the month-long DP-SCREAM 3 km simulation for August 2022, supplemented by a series of time-initialized runs starting on August 6 at 00:00, 06:00, 12:00, and 18:00 local time.